ReviewTrends in microbiology2010
BST-2/tetherin: a new component of the innate immune response to enveloped viruses.
Review in Trends in microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 201 citations in OpenAlex.
- Tetherin enforces an immunometabolic checkpoint that coordinates glycolytic and interferon signaling in adipocytes.bioRxiv : the preprint server for biology · 2026Article
- BST-2 inhibits SARS-CoV-2 egress at intracellular membranes and is neutralized by ORF7a.Scientific reports · 2026Article
- Elevated proportion of BST2 + CD4 + T cells: a potential biomarker for diagnosis and disease activity in Sjögren's disease.Clinical rheumatology · 2026Article
- Article
- Investigating conjunctival immune pathways in Sjögren and non-Sjögren disease associated dry eye.The ocular surface · 2026Article
- Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells.Nature communications · 2026Article
- Dynamics of antiretroviral restriction factor expression in sheep naturally infected with Small ruminant lentivirus (SRLV).Archives of virology · 2026Article
- Systemic removal of host restriction factors enables rapid, scalable virus production for cell culture-based vaccine development.Frontiers in bioengineering and biotechnology · 2026Article
- Article
- Characterization of a recombinant Sendai virus vector encoding the small ruminant lentivirus gag-P25: antiviral properties in vitro and transgene expression in sheep.Veterinary research · 2025Article
- The Deubiquitinase OTUD1 Influences HIV-1 Release by Regulating the Host Restriction Factor BST-2.Viruses · 2025Article
- The Role of Bone Marrow Stromal Cell Antigen 2 (BST2) in the Migration of Dendritic Cells to Lymph Nodes.International journal of molecular sciences · 2024Article
- BST2 facilitates activation of hematopoietic stem cells through ERK signaling.Experimental hematology · 2024Article
- A tale of endurance: bats, viruses and immune dynamics.Future microbiology · 2024Review
- Explore the shared molecular mechanism between dermatomyositis and nasopharyngeal cancer by bioinformatic analysis.PloS one · 2024Article
- Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.Neuro-oncology · 2023Article
- Article
- HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023Review
- Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes.Journal of virology · 2022Article
- TMEM106A inhibits enveloped virus release from cell surface.iScience · 2022Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The interferon-inducible, transmembrane protein BST-2 (CD317, tetherin) directly holds fully formed enveloped virus particles to the cells that produce them, inhibiting their spread. BST-2 inhibits members of the retrovirus, filovirus, arenavirus and herpesvirus families. These viruses encode a variety of proteins to degrade BST-2 and/or direct it away from its site of action at the cell surface. Viral antagonism has subjected BST-2 to positive selection, leading to species-specific differences that presented a barrier to the transmission of simian immunodeficiency viruses (SIVs) to humans. This barrier was crossed by HIV-1 when its Vpu protein acquired activity as a BST-2 antagonist. Here, we review this new host-pathogen relationship and discuss its impact on the evolution of primate lentiviruses and the origins of the HIV pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.